News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,638 Results
Type
Article (40965)
Company Profile (267)
Press Release (680396)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (204754)
Career Advice (2023)
Deals (35550)
Drug Delivery (110)
Drug Development (81544)
Employer Resources (173)
FDA (16408)
Job Trends (14944)
News (346611)
Policy (32738)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2568)
Accelerated approval (31)
Adcomms (24)
Allergies (137)
Alliances (49638)
ALS (168)
Alzheimer's disease (1661)
Antibody-drug conjugate (ADC) (307)
Approvals (16674)
Artificial intelligence (503)
Autoimmune disease (147)
Automation (37)
Bankruptcy (361)
Best Places to Work (11638)
BIOSECURE Act (20)
Biosimilars (188)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (632)
Cancer (4757)
Cardiovascular disease (395)
Career advice (1708)
Career pathing (35)
CAR-T (276)
CDC (44)
Celiac Disease (2)
Cell therapy (730)
Cervical cancer (36)
Clinical research (69620)
Collaboration (1671)
Company closure (4)
Compensation (1146)
Complete response letters (52)
COVID-19 (2722)
CRISPR (87)
C-suite (815)
Cystic fibrosis (143)
Data (6162)
Decentralized trials (2)
Denatured (25)
Depression (130)
Diabetes (497)
Diagnostics (6672)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (242)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (227)
Earnings (90046)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117266)
Executive appointments (959)
FDA (19491)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1446)
Gene editing (191)
Generative AI (42)
Gene therapy (585)
GLP-1 (962)
Government (4653)
Grass and pollen (6)
Guidances (383)
Healthcare (18900)
HIV (56)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (54)
Indications (104)
Infectious disease (2982)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (316)
IPO (16647)
IRA (49)
Job creations (3642)
Job search strategy (1428)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (547)
Leadership (30)
Legal (7952)
Liver cancer (91)
Longevity (14)
Lung cancer (640)
Lymphoma (372)
Machine learning (42)
Management (59)
Manufacturing (777)
MASH (161)
Medical device (13756)
Medtech (13808)
Mergers & acquisitions (19961)
Metabolic disorders (1253)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (309)
Neuropsychiatric disorders (86)
Neuroscience (2874)
Neurotech (1)
NextGen: Class of 2026 (6523)
Non-profit (4512)
Now hiring (65)
Obesity (587)
Opinion (258)
Ovarian cancer (165)
Pain (197)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (487)
Patient recruitment (472)
Peanut (55)
People (58836)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21741)
Phase 2 (30639)
Phase 3 (22815)
Pipeline (5107)
Policy (278)
Postmarket research (2566)
Preclinical (9214)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (277)
Rare diseases (818)
Real estate (5956)
Recruiting (69)
Regulatory (24433)
Reports (51)
Research institute (2387)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (146)
Series A (237)
Series B (185)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3616)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (997)
Venture capital (86)
Weight loss (377)
Women's health (87)
Worklife (18)
Date
Today (73)
Last 7 days (598)
Last 30 days (2011)
Last 365 days (29813)
2026 (2884)
2025 (30191)
2024 (35250)
2023 (40103)
2022 (51216)
2021 (55762)
2020 (54128)
2019 (46560)
2018 (35033)
2017 (32133)
2016 (31505)
2015 (37571)
2014 (31336)
2013 (26362)
2012 (28586)
2011 (29276)
2010 (27344)
Location
Africa (740)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39232)
Australia (6407)
California (11167)
Canada (3255)
China (1086)
Colorado (473)
Connecticut (470)
Delaware (332)
Europe (84655)
Florida (1663)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (852)
India (62)
Indiana (515)
Iowa (22)
Japan (419)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1369)
Massachusetts (8013)
Michigan (319)
Minnesota (622)
Mississippi (5)
Missouri (126)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2970)
New Mexico (28)
New York (2944)
North Carolina (1436)
North Dakota (8)
Northern California (5442)
Ohio (329)
Oklahoma (21)
Oregon (41)
Pennsylvania (2254)
Puerto Rico (22)
Rhode Island (47)
South America (1108)
South Carolina (65)
South Dakota (1)
Southern California (4347)
Tennessee (172)
Texas (1723)
United States (39600)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
721,638 Results for "immunogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity
BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees working on the program have been redeployed within the company.
August 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges
January 21, 2026
·
2 min read
Press Releases
EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide
December 9, 2025
·
2 min read
Press Releases
GC Biopharma’s Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in ‘Vaccine’
November 3, 2025
·
4 min read
Press Releases
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
September 3, 2025
·
10 min read
Press Releases
Nouscom to Present New Positive Phase 1b/2 Clinical and Translational Data on NOUS-209 Immunogenicity and Cancer Interception Potential in Lynch Syndrome Carriers at SITC 2025
October 31, 2025
·
7 min read
Press Releases
Novavax’s H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
July 25, 2025
·
6 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of January 31, 2024, the grant of restricted stock units covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to eleven new employees.
February 1, 2024
·
1 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of December 29, 2023, the grant of restricted stock units covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc.
January 3, 2024
·
1 min read
Deals
AbbVie Completes Acquisition of ImmunoGen
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN).
February 12, 2024
·
8 min read
1 of 72,164
Next
